Hello every one…i was going through the AR 2016-17 of bliss pharma and saw the following note in their notes to non current investment at page no. 79…
Can anyone throw a light onto the implication of such an investment…This further boosts my doubts about validity of investing in non listed subsidiary companies which are not performing too…
shall we count such investments for the purpose of DCF and other valuation models…
Bliss is proposing to sell it’s clinic operations in Africa which forms
between 40 - 50% of the sales and profits of the company… Can some
boarders who have studied bliss in detail explain why the stock is still
holding…when the profits and sales are going to be about half in the not
so distant future…
After reading the 2016-17 AR, i have following observations -
The bliss pharma ltd has made a net profit of 62 cr while the kenya subsidiary which has been sold has earned arnd 61 cr too.
After its sell. the profits will be almost halved.
The new acquisition is a small company which cant produce the profits of 60 cr.
This means that the earnings will be halved and so the share price…
this is my thought process as a novice…i request any senior member to throw some light…
regards
Anyone having latest on bilssgvs. Charts are giving some good signals , volume for month Feb2019 is record breaking high indicating very keen interest of mkt in this scrip.
Promoter holding fell from 60.16% in June18 to 41.53% in June 19.
Narsimha Shibroor Kamath reduced his stake from 40.74% to 33.31%.
Any rationale for such drastic reduction in PH?
@ayushmit or anyone, are you still tracking this?
Can we discuss the key risks here?
They have a huge spike in their margins for Dec 2019 quarter and the earning after tax will be almost similar to the last year on the account of reduced revenues.
Looking to expand the discussion on this.
I stopped tracking this co few years back, sorry, not much idea currently
What is cooking here? Anyone know the management? Is this company a fraud?
I called up the Company Sec. She said management doesnt meet - if you want to invest then its your choice.
Hi, is anyone still tracking this company? The stock has been buzzing in trade over the last few weeks? Any key development?
Got GMP clearence and some capex activity after many years. Check CWIP in Sept
All the incremental capex that has come from 2022 caters to reg markets, and now 30 crs worth more of capacity approved for their semi solid and oral solids facilities. Check recent AGM
Please share the link for the AGM / notes from AGM
dr.vikas
Didn’t take any notes sir but here’s the website for AGM recordings : Annual General Meeting – Bliss GVS Pharma Limited
Thanks a lot for sharing it.
dr.vikas
Resignation of Managing Director:
The Board has noted and accepted the resignation of Mr. Gagan Harsh Sharma
(DIN: 07939421) from the position of Managing Director of the Company with immediate effect
i.e. November 06, 2025, due to other professional commitments.
Consequently, Mr. Sharma shall also cease to be a member of the Audit Committee, Corporate
Social Responsibility Committee and Risk Management Committee of the Company with effect
from the same date.
The followup development is more important, if Bliss hires outside professional for MD position then it would be positive in my view. Mr. Gagan sharma is son in law of Mr. Narsimha kamath so it’s really very strange of him going out. As company is not doing any concall so we need to wait and watch the next step.
Performance is improved in last 2 years, so I hope management won’t do any thing stupid..
Bliss GVS Pharma Limited reappoints S. N. Kamath as Managing Director for three years, subject to shareholder approval. Kamath is the promoter of Bliss GVS Pharma Limited and is presently associated with the company as its Chief Executive Office. He is the father of Whole-Time Directors Dr. Vibha Gagan Sharma and Mrs. Shruti Vishal Rao.
Please find the report from seven canyons reg company.AEC Commentary (Q3 2025) — Seven Canyons Advisors
